At Ambu's annual general meeting in December 2006, the Board of Directors was
authorised to increase the company's Class B share capital by a total nominal
amount of up to DKK 2,000,000 in the form of bonus shares issued to Ambu
employees, cor-responding to 200,000 Class B shares of DKK 10 each to be
subscribed by the group's employees and with no preemptive right of
subscription for the company's current shareholders.
The Board of Directors has decided to act upon this authorisation on the terms
speci-fied. Eligible employees can subscribe for a number of shares at a price
of DKK 55 per share (on 14 March 2007 the market price was 99,50).
Subscription of employee shares will take place during the period 16-20 April
2007, and the capital increase will be registered immediately, the shares being
listed on the Copenhagen Stock Exchange.
The employee shares will carry the same rights as Ambu's existing Class B
shares.
Once the subscription is complete, information will be provided on the
financial con-sequences of the programme.
Contact: K.E. Birk, tel. no. +45 7225 2000, email keb@ambu.com
Ambu develops, produces and markets diagnostic and life-supporting devices to
hospitals and rescue services. Ambu has five business areas: Respiratory Care,
Cardiology, Neurology, Train-ing and Immobilization. The most important
business areas are Respiratory Care, Cardiology and Neurology, and the most
important products in these areas are ventilation products for artificial
respiration and single-use electrodes for ECG recordings and neurophysiological
exami-nations. Ambu's products are sold worldwide. Exports account for 98% of
sales, and sales are handled via Ambu's foreign subsidiaries or via
distributors. Ambu has 1,200 employees of whom 300 work in Denmark and 900 work
abroad.
